Comments
Strides Shasun on Wednesday said that it will launch Ranitidine tablets USP, 75 mg (OTC) for the US markets. Strides is already a key player with 32 per cent share of the US Rx market for Ranitidine.
According to IRI data, the US OTC market for Ranitidine tablets, which is the generic form of the popular brand Zantac, is approximately $200 million, the company said in a statement.
This is the second product approval from the company’s 50:50 joint venture with Vivimed Labs.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.